Abstract
Objective To investigate the clinical efficacy and safety of bevacizumab, apatinib, and recombinant human endothelial inhibitor in the treatment of advanced gastric cancer. Methods The medical data of 204 patients with a medium to advanced gastric cancer assessed for eligibility treated in our hospital from February 2019 to April 2020 were retrospectively analyzed. The eligible patients were assigned at a ratio of 1 : 1:1 : 1 to either the control group (chemotherapy), study group I (bevacizumab combined with chemotherapy), study group II (apatinib combined with chemotherapy), or study group III (recombinant human endothelial inhibitor combined with chemotherapy) according to different treatment methods. The treatment efficacy, drug toxicity, quality of life, and serum tumor marker levels before and after treatment were compared among the four groups. Results Regarding the treatment effects, the effective rate of study group II (68.63%) was significantly higher than that of the control group (33.33%), study group I (58.82%), and study group III (49.02%) (P < 0.05). The four groups showed similar safety and tolerability profiles (P > 0.05). The treatment in study group II led to a significantly higher physiological function score vs. the other three groups, but the scores of other items were not significantly different. Significant reduction was observed in the serum tumor markers after treatment in the four groups (P < 0.05), but treatment in study group II led to a significantly greater reduction than the other three groups (P < 0.05). Conclusion The addition of apatinib, bevacizumab, and recombinant human endothelial inhibitor injection to chemotherapy for the treatment of medium to advanced gastric cancer can significantly improve the clinical treatment efficacy, among which the use of apatinib combined with chemotherapy achieves the best results, which is worthy of clinical promotion.
Highlights
Gastric cancer is a common gastrointestinal malignancy, with its prevalence and mortality rate ranking first among all malignancies in China
This study included 204 patients with medium and advanced gastric cancer treated in our hospital from February 2019 to April 2020 as research subjects to evaluate the clinical efficacy and safety of bevacizumab, apatinib, and recombinant human endothelial inhibitor in treating advanced gastric cancer
General Data. 204 patients with a medium to advanced gastric cancer treated in our hospital from February 2019 to April 2020 were identified as research subjects and were assigned to either control group, study group I, study group II, or study group III according to different treatment methods, with 51 cases in each group. is study was approved by the ethics committee of our hospital. e inclusion criteria for all study subjects were as follows: patients who were diagnosed with gastric cancer confirmed by pathological and cytological tests, patients aged between 30 and 80 years, and patients with an expected survival of more than 3 months
Summary
Gastric cancer is a common gastrointestinal malignancy, with its prevalence and mortality rate ranking first among all malignancies in China. For patients with advanced gastric cancer, disease control can only be achieved by chemotherapy. Remarkable efficiency has been achieved by targeted therapy in disease control of tumors. Bevacizumab is a new molecularly targeted antitumor drug in clinical practice, with promising antitumor effects as evidenced by current research reports and data [3,4,5]. E new recombinant human vascular endothelial inhibitor (Endostar) is a multitarget vascular endothelial inhibitor developed independently in China, which has obtained significant efficacy in Journal of Oncology the treatment of lung cancer. This study included 204 patients with medium and advanced gastric cancer treated in our hospital from February 2019 to April 2020 as research subjects to evaluate the clinical efficacy and safety of bevacizumab, apatinib, and recombinant human endothelial inhibitor in treating advanced gastric cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
